View Cart  
Fdanewsdrugdailybulletin

April 24, 2014

Vol. 11 No. 81

View Archived Issues

Sign Up Now

Spectrum Pharmaceuticals’ Captisol-Enabled Melphalan Meets Endpoint in Pivotal Trial

The drugmaker said that its Melphalan is free of propylene glycol, which is associated with cardiac and renal failure. Read More

Hospira Recalls Lot of Marcaine Due to Particulates

Hospira has initiated yet another recall of a drug due to discoloration and visible particulate matter embedded in glass vials. Read More

Frenetic Activity Won’t Fix the Pharmaceutical Industry’s Problems

The pharmaceutical sector is creating more excitement in the world’s financial centers than the opening of a warehouse full of free Viagra in a retirement community. Read More

FDA Looks for Stakeholder Input on Trials Meant to Assess Abuse of Opioids

The FDA has experienced no shortage of criticism in recent years about its regulation of opioid-based painkillers in light of the drugs’ contribution to what the Centers for Disease Control and Prevention calls an “epidemic of prescription painkiller abuse.” Read More

Heat-Stable Vaccines Urgently Needed to Reach the One in Five Children Missed By Immunization Worldwide

The need for vaccines to be kept constantly cold is proving a major barrier in improving poor immunization coverage rates, with one in five children born each year missing out on life-saving vaccinations, Médecins Sans Frontières said Tuesday. Read More

FDA Panel Rejects Combination Pain Pill

Federal health advisers have unanimously rejected an experimental pain pill that combines two common opioids, oxycodone and morphine. Read More

Thunder God Vine Works as Well as a Western Drug for Rheumatoid Arthritis

To ease the pain and swelling of rheumatoid arthritis, how might an ancient Chinese herbal remedy, made from an extract of thunder god vine, compare with methotrexate, a modern drug commonly prescribed to treat the disease? Read More

Sagent Reintroduces Adenosine Injection With Improved Prefilled Plastic Syringes

Sagent Pharmaceuticals has reintroduced Adenosine Injection, USP, an antiarrhythmic agent, with improved prefilled plastic syringes. Read More